Back to Search
Start Over
Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy
- Source :
- Cancer Medicine, Vol 7, Iss 7, Pp 2943-2950 (2018), Cancer Medicine
- Publication Year :
- 2018
- Publisher :
- Wiley, 2018.
-
Abstract
- Most patients receiving highly or moderately emetogenic chemotherapy experience chemotherapy‐induced nausea and vomiting without antiemetic prophylaxis. While neurokinin‐1 receptor antagonists (NK‐1RAs) effectively prevent emesis, their ability to prevent nausea has not been established. We evaluated the efficacy of the long‐acting NK‐1RA rolapitant in preventing chemotherapy‐induced nausea using post hoc analyses of data from 3 phase 3 trials. Patients were randomized to receive 180 mg oral rolapitant or placebo approximately 1‐2 hours before chemotherapy in combination with a 5‐hydroxytryptamine type 3 RA and dexamethasone. Nausea was assessed by visual analog scale during the acute (≤24 hours), delayed (>24‐120 hours), and overall (0‐120 hours) phases. Post hoc analyses by treatment group (rolapitant vs control) were performed on pooled data within patient subgroups receiving cisplatin‐based, carboplatin‐based, or anthracycline/cyclophosphamide (AC)‐based chemotherapy. In the cisplatin‐based chemotherapy group, significantly more patients receiving rolapitant than control reported no nausea (NN) in the overall (52.3% vs 41.7% [P
- Subjects :
- Cancer Research
medicine.medical_specialty
Cyclophosphamide
Nausea
medicine.drug_class
medicine.medical_treatment
cisplatin
Rolapitant
Gastroenterology
neurokinin‐1 receptor antagonist
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
rolapitant
Internal medicine
Medicine
Antiemetic
chemotherapy‐induced nausea and vomiting
Radiology, Nuclear Medicine and imaging
030212 general & internal medicine
RC254-282
Original Research
anthracycline/cyclophosphamide
Chemotherapy
highly emetogenic chemotherapy
moderately emetogenic chemotherapy
business.industry
Clinical Cancer Research
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
nausea
Carboplatin
Oncology
chemistry
030220 oncology & carcinogenesis
carboplatin
Vomiting
medicine.symptom
business
medicine.drug
Chemotherapy-induced nausea and vomiting
Subjects
Details
- ISSN :
- 20457634
- Volume :
- 7
- Database :
- OpenAIRE
- Journal :
- Cancer Medicine
- Accession number :
- edsair.doi.dedup.....84f37ebbccc4e9ad719b05c03df04600